Insulet

Insulet Corp. is a medical device company, which engages in the development, manufacture, and marketing of an insulin infusion system for people with insulin-dependent diabetes. It specializes in diabetes supplies, including the OmniPod System, as well as other diabetes related products and supplies such as blood glucose testing supplies, traditional insulin pumps, pump supplies, and pharmaceuticals. The company was founded by John L. Brooks III and John T. Garibotto in July 2000 and is headquartered in Acton, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Insulet (PODD) reports record-breaking Q4 earnings, eyes international expansion

Insulet's Q4 2022 earnings call highlighted exceptional revenue growth, strong customer adoption of Omnipod 5, and a focus on customer-centric innovation. While facing challenges with device corrections and FDA approval timelines, the company remains optimistic about revenue growth, margin improvement, and strategic investments in innovation and expansion.

Insulet reports robust Q1 growth, eyes global expansion opportunities

Insulet's Q1 2023 showcased strong financials, driven by Omnipod 5 success and U.S. market growth.
Optimism for future growth, market leadership, and expansion into underpenetrated global markets.
Challenges include declining drug delivery business and the need for continued innovation and market penetration strategies.

Insulet reports robust Q2 earnings, eyes European expansion and innovation

Insulet's Q2 performance exceeded expectations, driven by strong revenue growth and the success of Omnipod 5, showcasing the company's market strength and innovation.
While facing challenges such as inventory management and uncertainties around new products like Omnipod GO, Insulet remains optimistic about its growth trajectory and international expansion.
The company's strategic focus on consumer needs, continuous innovation, and expansion into new markets position it well for sustained leadership and revenue growth in the diabetes management sector.

Insulet excels in Q3 with Omnipod 5 driving growth

Insulet's Q3 performance was robust, driven by Omnipod 5 success.
Confidence in growth outlook, financial strength, and market positioning.
Challenges include competition, timing guidance, and market penetration.
Opportunities lie in basal market expansion and international growth potential.

Insulet (PODD) reports stellar Q4 results and eyes global expansion

Insulet's Q4 2023 performance was robust, driven by strong revenue growth and milestone achievements.
The company's strengths lie in its focus on innovation, market positioning, and strategic partnerships.
Challenges include optimizing resource allocation, reimbursement negotiations, and meeting high demand.
Opportunities for Insulet include expanding digital capabilities, driving innovation, and capturing market growth.

Insulet (PODD) reports record Q3 revenue and outlines growth strategies

Insulet's Q3 performance exceeded expectations with strong revenue and margin growth.
The company's focus on expanding Omnipod 5 platform and international growth is key.
Challenges include maintaining growth rates and sustaining pricing benefits.
Opportunities lie in accelerating international expansion and enhancing customer experience.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Advance Auto Parts

Bio-Rad Laboratories

Catalent

Dollar General

Estee Lauder

Enphase Energy

Etsy

KeyCorp

MarketAxess Holdings

Mosaic

Moderna

Newell Brands

Paramount Global

ResMed

SolarEdge Technologies

Sealed Air

Walgreens

Window dressing is a deceitful practice where mutual funds and other large institutions buy high-flying stocks and sell off the losing ones just before the end of a quarter, when many funds must report their holdings.

These Stocks Could Face Selling Pressure Soon

Insulet's (PODD) international expansion efforts are aligned with its long-term growth profile.

Insulet (PODD) Expands Omnipod 5 Even As Macro Woes Linger

Insulet's CEO stated today that new diabetes drugs could impact how quickly patients begin insulin therapy. However, the company doesn't expect any long-term impact on sales of its insulin pumps.

Why Insulet Stock Is Sinking Today

Insulin pumps maker Insulet Corp said on Thursday a new generation of diabetes drugs, known as GLP-1s, could delay the time that diabetes patients become dependent on insulin, sending its shares down 10%.

Insulet shares slump on concerns of sales hit from new diabetes drugs

Tapestry

Insulet is seeing increasing price pressure in the insulin market ResMed missed estimates on the top and bottom lines. Investors balked at Tapestry's acquisition of Capri.

Is It Time to Buy the S&P 500's 3 Worst-Performing August Stocks?

Shockwave Medical

Transmedics Group Inc

The healthcare sector has underperformed this year, with the Health Care Select Sector SPDR (NYSEARCA: XLV ) down 1%. After a disappointing year-to-date performance, it's time to consider some top healthcare stock picks.

The 3 Most Promising Healthcare Stocks to Own Now

The medical device specialist's CEO made a large purchase in its stock on Monday. The total outlay for the shares topped $1 million.

Why Insulet Stock Rocked the Market Today

Insulet's (PODD) Omnipod 5 is available in the United States and the United Kingdom.

Insulet (PODD) Launches Omnipod 5 AID System in Germany

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod brand of products, today announced the commercial launch of its Omnipod 5 Automated Insulin Delivery System (Omnipod 5) for individuals aged two years and older with type 1 diabetes (T1D) in its third market, Germany. Omnipod 5 is also available in the U.S. and the U.K. “We know people in Germany living with type 1 diabetes want the m.

Insulet Announces Full Market Release of Omnipod® 5 Automated Insulin Delivery System in Germany

Insulet Corporation has seen a 30% drop in its shares despite solid Q2 earnings and strong commercial traction. The company aims to simplify the lives of people with diabetes and reduce the burden on the healthcare system. Sales have grown from $200 million in 2012 to $1 billion in 2021, but the share price has outpaced revenue and earnings (per share) growth.

Insulet: Losing More Weight

Medtronic

Investors interested in Medical - Products stocks are likely familiar with Medtronic (MDT) and Insulet (PODD). But which of these two stocks offers value investors a better bang for their buck right now?

MDT or PODD: Which Is the Better Value Stock Right Now?

Insulet's (PODD) Omnipod 5 gains market share in the second quarter within the diabetes technology market as the only FDA-approved fully disposable, pod-based automated insulin delivery system.

Insulet (PODD) Q2 Earnings Beat, Sales Growth View Raised

Insulet Corporation (NASDAQ:PODD ) Q2 2023 Earnings Conference Call August 8, 2023 4:30 PM ET Company Participants Deborah Gordon - VP, IR James Hollingshead - President, CEO & Director Wayde McMillan - EVP, CFO & Treasurer Conference Call Participants Lawrence Biegelsen - Wells Fargo Securities Robert Marcus - JPMorgan Chase & Co. Malgorzata Kaczor - William Blair & Company Joshua Jennings - TD Cowen Danielle Antalffy - UBS Jeffrey Johnson - Robert W. Baird & Co. Michael Sarcone - Jefferies Christopher Pasquale - Nephron Research Matthew O'Brien - Piper Sandler & Co. Matthew Miksic - Barclays Bank Steven Lichtman - Oppenheimer Joanne Wuensch - Citigroup Doyle Shell - Raymond James & Associates Travis Steed - Bank of America Merrill Lynch Operator Good afternoon, ladies and gentlemen, and welcome to the Insulet Corporation Second Quarter 2023 Earnings Call.

Insulet Corporation (PODD) Q2 2023 Earnings Call Transcript

Insulet (PODD) came out with quarterly earnings of $0.38 per share, beating the Zacks Consensus Estimate of $0.24 per share. This compares to loss of $0.06 per share a year ago.

Insulet (PODD) Tops Q2 Earnings and Revenue Estimates

The headline numbers for Insulet (PODD) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Here's What Key Metrics Tell Us About Insulet (PODD) Q2 Earnings

Insulet Corp on Tuesday raised its annual revenue growth forecast and beat second-quarter profit and revenue estimates, on strong demand for its tubeless insulin pumps that are more convenient to use compared to traditional devices.

Insulet lifts sales growth forecast on strong demand for insulin pumps

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced financial results for the three months ended June 30, 2023. Second Quarter Financial Highlights: Second quarter 2023 revenue of $396.5 million, up 32.4%, or 32.2% in constant currency1, compared to $299.4 million in the prior year Total Omnipod revenue of $380.5 million, an increase of 33.2%, or 33.

Insulet Reports Second Quarter 2023 Revenue Increase of 32% Year-Over-Year (32% Constant Currency1)

Darden Restaurants

EPAM Systems

Lowe's

Motorola Solutions

Norwegian Cruise Line

Sysco

Walmart

August isn't a great month for the S&P 500 — it's actually the third-worst month of the year. But savvy investors can still pick up big gains.

8 Stocks Thrive In August — As The Rest Of The S&P 500 Withers

Alphabet

Tandem Diabetes Care

Investing in high-growth businesses can be a way for investors to maximize their long-term returns. Diabetes care and artificial intelligence represent two big growth opportunities in the future.

Where to Invest $5,000 for the Next 20 Years

DexCom

Paycom Software

Apple

Arch Capital

Best Buy

Broadridge Financial

Salesforce

Cintas Corp

Keysight

Monolithic Power Systems

Microsoft

Nasdaq

Netflix

NetApp

NVIDIA

Synopsys

Take-Two Interactive Software

Subscribers to  Chart of the Week  received this commentary on Sunday, July 23.

25 S&P 500 Stocks to Target Next Month

Zimmer Biomet Hlds

Investors interested in stocks from the Medical - Products sector have probably already heard of Zimmer Biomet (ZBH) and Insulet (PODD). But which of these two companies is the best option for those looking for undervalued stocks?

ZBH or PODD: Which Is the Better Value Stock Right Now?

Aptiv

Cadence Design Systems

Chipotle

Fortinet

Intuit

ServiceNow

ServiceNow and Chipotle Mexican Grill are among just eight S&P 500 stocks that meet Goldman Sachs' Rule Of 10 screens for sales and net income.

Just 8 S&P 500 Stocks Make These Goldman 'Rule Of 10' Screens

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced plans to release its financial results for the second quarter of 2023 on August 8, 2023 after the close of the financial markets. In connection with the release, management will host a conference call that day at 4:30 p.m. (Eastern Time). The link to the live call will be available on the Investor R.

Insulet to Announce Second Quarter 2023 Financial Results on August 8, 2023

Palo Alto Networks

“Can tech keep up the pace?” is a burning question for many with regards to a sector that helped drive the S&P 500 SPX, +0.12% to its best first half since 2019.

These stocks could be the next Magnificent Seven market leaders, says Goldman Sachs

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod brand of products, today announced an exciting lineup of events and product developments that will be discussed at the American Diabetes Association (ADA) 83rd Scientific Sessions in San Diego, California, including new real-world evidence (RWE) of improved outcomes and optimization of care using the Omnipod 5 Automated Insulin Delive.

Insulet Celebrates One Year of Omnipod® 5 at the American Diabetes Association 83rd Scientific Sessions

News for Insulet Stock (PODD)